OBJECTIVE: We examined whether nonadherence to hydroxychloroquine (HCQ) or immunosuppressive medications (ISMs) was associated with higher subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus (SLE). METHODS: We utilized US Medicaid data from 2000-2006 to identify adults ages 18-64 years with SLE who were new users of HCQ or ISMs. We defined the index date as receipt of HCQ or ISMs without use in the prior 6 months. We measured adherence using the medication possession ratio (MPR), the proportion of days covered by total days' supply dispensed, for the 1-year post-index date. Our outcomes were all-cause and SLE-related emergency department (ED) visits and hospitalizations in the subsequent year. We used multivariable Poisson regression models to examine the association between nonadherence (MPR <80%) and acute care utilization, adjusting for sociodemographics and comorbidities. RESULTS: We identified 9,600 HCQ new users and 3,829 ISM new users with SLE. The mean ± SD MPR for HCQ was 47.8% ± 30.3% and for ISMs was 42.7% ± 30.7%. Seventy-nine percent of HCQ users and 83% of ISM users were nonadherent (MPR <80%). In multivariable models, among HCQ users, the incidence rate ratio (IRR) of ED visits was 1.55 (95% confidence interval [95% CI] 1.43-1.69) and the IRR of hospitalizations was 1.37 (95% CI 1.25-1.50), comparing nonadherers to adherers. For ISM users, the IRR of ED visits was 1.64 (95% CI 1.42-1.89) and of hospitalizations was 1.67 (95% CI 1.41-1.96) for nonadherers versus adherers. CONCLUSION: In this cohort, nonadherence to HCQ and ISMs was common and was associated with significantly higher subsequent acute care utilization.
OBJECTIVE: We examined whether nonadherence to hydroxychloroquine (HCQ) or immunosuppressive medications (ISMs) was associated with higher subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus (SLE). METHODS: We utilized US Medicaid data from 2000-2006 to identify adults ages 18-64 years with SLE who were new users of HCQ or ISMs. We defined the index date as receipt of HCQ or ISMs without use in the prior 6 months. We measured adherence using the medication possession ratio (MPR), the proportion of days covered by total days' supply dispensed, for the 1-year post-index date. Our outcomes were all-cause and SLE-related emergency department (ED) visits and hospitalizations in the subsequent year. We used multivariable Poisson regression models to examine the association between nonadherence (MPR <80%) and acute care utilization, adjusting for sociodemographics and comorbidities. RESULTS: We identified 9,600 HCQ new users and 3,829 ISM new users with SLE. The mean ± SD MPR for HCQ was 47.8% ± 30.3% and for ISMs was 42.7% ± 30.7%. Seventy-nine percent of HCQ users and 83% of ISM users were nonadherent (MPR <80%). In multivariable models, among HCQ users, the incidence rate ratio (IRR) of ED visits was 1.55 (95% confidence interval [95% CI] 1.43-1.69) and the IRR of hospitalizations was 1.37 (95% CI 1.25-1.50), comparing nonadherers to adherers. For ISM users, the IRR of ED visits was 1.64 (95% CI 1.42-1.89) and of hospitalizations was 1.67 (95% CI 1.41-1.96) for nonadherers versus adherers. CONCLUSION: In this cohort, nonadherence to HCQ and ISMs was common and was associated with significantly higher subsequent acute care utilization.
Authors: Sri Koneru; Michael Shishov; Avis Ware; Yolanda Farhey; Anne-Barbara Mongey; T Brent Graham; Murray H Passo; J Lawrence Houk; Gloria C Higgins; Hermine I Brunner Journal: Arthritis Rheum Date: 2007-08-15
Authors: Theresa L Walunas; Kathryn L Jackson; Anh H Chung; Karen A Mancera-Cuevas; Daniel L Erickson; Rosalind Ramsey-Goldman; Abel Kho Journal: Arthritis Care Res (Hoboken) Date: 2017-08-08 Impact factor: 4.794
Authors: Candace H Feldman; Karen H Costenbader; Daniel H Solomon; S V Subramanian; Ichiro Kawachi Journal: Arthritis Care Res (Hoboken) Date: 2019-07 Impact factor: 4.794
Authors: Cianna Leatherwood; Cameron B Speyer; Candace H Feldman; Kristin D'Silva; José A Gómez-Puerta; Paul J Hoover; Sushrut S Waikar; Gearoid M McMahon; Helmut G Rennke; Karen H Costenbader Journal: Semin Arthritis Rheum Date: 2019-06-11 Impact factor: 5.532
Authors: Stephen J Balevic; Michael Cohen-Wolkowiez; Amanda M Eudy; Thomas P Green; Laura E Schanberg; Megan E B Clowse Journal: J Rheumatol Date: 2018-10-01 Impact factor: 4.666
Authors: Candace H Feldman; Jamie Collins; Zhi Zhang; Chang Xu; S V Subramanian; Ichiro Kawachi; Daniel H Solomon; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2019-11 Impact factor: 4.794
Authors: Candace H Feldman; Jamie Collins; Zhi Zhang; S V Subramanian; Daniel H Solomon; Ichiro Kawachi; Karen H Costenbader Journal: Semin Arthritis Rheum Date: 2018-01-08 Impact factor: 5.532